JSCO2022 ”Frontier”

TOP > JSCO2022 ”Frontier”

JSCO2022 "Frontier" 1
GI Colorectal Cancer
Oct 20 (Thu.) 16:20~18:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Akihito Tsuji (Medical oncology, Faculty of Medicine, Kagawa University)
Eiji Oki (Surgery and Science, Graduate School, Kyushu University)
Ruihua Xu (Sun Yat-sen University Cancer Center, China)
The subgroup analysis of tumor response by BRAF status in modified (m)-FOLFOXIRI plus cetuximab vs. bevacizumab for RAS wild-type metastatic colorectal cancer (mCRC): the DEEPER trial (JACCRO CC-13)
Speaker: Mitsuyoshi Tei
(Department of Surgery, Osaka Rosai Hospital)
Results of an open-label, safety lead-in cohort of Japanese patients in FRESCO-2: A global phase 3 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer (mCRC)
Speaker: Daisuke Kotani
(National Cancer Center Hospital East)
Molecular residual disease may be a strong predictor for recurrence in rectal cancer with upfront surgery: result from the observational GALAXY study in CIRCULATE-Japan project
Speaker: Koji Ando
(Department of Colorectal Cancer Surgery, National Cancer Center Hospital East)
Takeshi Yamada (Department of Digestive Surgery, Nippon Medical School)
Impact of R0 resection (R0) on overall survival (OS) in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): results from PARADIGM
Speaker: Jun Watanabe
(Gastroenterological Center, Yokohama City University Medical Center)
Impact of left colic artery preservation on bowel perfusion and anastomotic leakage in minimally invasive rectal cancer surgery: results from EssentiAL study
Speaker: Masataka Ikeda
(Division of Lower GI, Department of Gastroenterological Surgey, Hyogo Medical University)
JSCO2022 "Frontier" 2
Gynecological Cancer
Oct 21 (Fri.) 15:30~16:30 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)
Mayu Yunokawa (The Department of gynecology Oncology,
The Cancer Institute Hospital)
Phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab (CEMI) in recurrent or metastatic (R/M) cervical cancer: Subgroup analysis of patients (pts) enrolled in Japan
Speaker: Kosei Hasegawa
(Department of Gynecologic Oncology, International Medical Center, Saitama Medical niversity)
Pembrolizumab Plus Chemotherapy With/Without Bevacizumab in East Asian Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analysis From the Phase 3 KEYNOTE-826 Study
Speaker: Shin Nishio
(Department of Obstetrics and Gynecology, Kurume University School of Medicine)
Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma; Multicenter phase II investigator-initiated trial (STATICE TRIAL, NCCH1615)
Speaker: Tadaaki Nishikawa
(Department of Medical Oncology, National Cancer Center Hospital)
JSCO2022 "Frontier" 3
Oct 21 (Fri.) 16:30~17:30 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Yoichi Naito (National Cancer Center Hospital East)
Katsuya Tsuchihara (Division of Translational Informatics,
Exploratory Oncology Research and Clinical Trial Center,
National Cancer Center)
Gut microbiome associated with BRCA1/2 mutation and response to PARP inhibitor in ovarian cancer: SCRUM-Japan MONSTAR-SCREEN
Speaker: Mika Sakai
(Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center)
Gut microbiome comparison between metastatic breast cancer and other cancers, and its association with subtype and efficacy of immune checkpoint inhibitors
Speaker: Hiroyuki Yasojima
(Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital)
Feasibility and Potential Clinical Utility of Multi-omics Analysis for Advanced Solid Tumors: Preliminary Results of the SCRUM-Japan MONSTAR-SCREEN-2
Speaker: Takao Fujisawa
(Translational Research Support Office, National Cancer Center Hospital East)
JSCO2022 "Frontier" 4
GI Non-colorectal Cancer, Head & Neck Cancer
Oct 22 (Sat.) 8:00~9:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Yoshiaki Nakamura (National Cancer Center Hospital East)
Hideaki Bando (Department of Gastroenterology and
Gastrointestinal Oncology, National Cancer Center hospital East)
Nivolumab + chemotherapy or ipilimumab vs chemotherapy as first-line advanced esophageal squamous cell carcinoma treatment: expanded efficacy and safety analyses from CheckMate 648 Japanese subgroup
Speaker: Ken Kato
(National Cancer Center Hospital)
First-line nivolumab plus chemotherapy vs chemotherapy for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: survival analyses by tumor response from CheckMate 649
Speaker: Kensei Yamaguchi
(The Cancer Institute Hospital of JFCR)
Biomarker Analysis with Next Generation Sequencing (NGS) in YATAGARASU, the Phase 2 Study of Apalutamide (APA) plus Goserelin (GOS) for Androgen Receptor (AR)-expressing Salivary Gland Carcinoma (SGC)
Speaker: Yoshitaka Honma
(Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)
JSCO2022 "Frontier" 5
Genitourinary Cancer
Oct 22 (Sat.) 9:00~10:00 Room 2 (Ohwada A, Portopia Hotel South Bldg. 1F)
Masatoshi Eto (Department of Urology, Graduate School of Medical
Sciences, Kyushu University)
Kazutoshi Fujita (Kindai University)
Efficacy and safety of adjuvant pembrolizumab versus placebo for patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy in the KEYNOTE-564 East Asian subgroup
Speaker: Hiroshi Kitamura
(University of Toyama)
Time course and incidence of common adverse events in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Speaker: Bertrand Tombal
(Cliniques Universitaires Saint Luc, UCLouvain, Belgium)
The comprehensive analysis of gut microbiome and clinical outcomes in patients with metastatic castration-sensitive and -resistant prostate cancer
Speaker: Nobuaki Matsubara
(National Cancer Center East)